• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Walgreens Boots Alliance Announces Leadership Transition

    9/1/23 7:30:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email

    Rosalind Brewer Steps Down as CEO and Member of the Board

    Ginger Graham, Current Lead Independent Director, Appointed Interim CEO

    Search Process to Identify a Permanent CEO Is Underway

    Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that the Board of Directors and Rosalind Brewer have mutually agreed that Ms. Brewer will step down as the Company's Chief Executive Officer (CEO) and as a member of the Board, as of August 31, 2023. The Board has appointed Ginger Graham, current Lead Independent Director of WBA, as the Company's interim CEO. Ms. Brewer has agreed to continue to advise WBA while the Company conducts a search for a permanent CEO.

    Stefano Pessina, Executive Chairman, WBA, said, "On behalf of the entire Board, I would like to thank Roz for her contributions to WBA. Roz navigated the Company through the global pandemic, overseeing the critical rollout of vaccines in Walgreens pharmacies and to high-risk populations across the country. She furthered our consumer facing capabilities while supporting the culture of community and team-member engagement in difficult times. We appreciate her hard work and commitment to the Company during this period of unprecedented change."

    Ms. Brewer said, "I am grateful to have had the opportunity to lead Walgreens Boots Alliance and to work alongside such talented and dedicated colleagues. I am proud of what we accomplished together. We've improved the lives of our employees, expanded healthcare services for our customers and enhanced our ability to deliver on our purpose of ‘more joyful lives through better health.' Over the past several years, we have recruited a world class team to WBA, including the first-ever Chief Customer Officer and the first-ever President of U.S. Healthcare, and invested deeply in the improvement of the Company's overall culture. I am confident that WBA is on track to be a leading consumer-centric healthcare company, serving thousands of communities across the country, especially those that need access to healthcare the most. I look forward to watching the Company continue its transformation to deliver localized healthcare."

    Roz Brewer was named Chief Executive Officer of WBA in March 2021, just as COVID-19 vaccines were becoming available to the American people. She built and led a team to stand up the technology for a vaccine scheduling system, created a safe operating model for store labor, and developed a plan to drive vaccine equity. To date, WBA has delivered over 70 million vaccine shots. In October 2021, Ms. Brewer and her team introduced a significant strategic pivot towards the growth of WBA into healthcare, including three strategic acquisitions to expand and accelerate WBA's consumer-centric healthcare offerings. During her tenure the company also achieved considerable cost savings through its transformational cost management program.

    The Board's process to identify a new CEO is underway with the support of a leading global executive search firm.

    Ginger Graham Named Interim CEO of Walgreens Boots Alliance

    "Ginger is the ideal person to serve as interim CEO, given her leadership experience across multiple segments of the healthcare industry, deep knowledge of WBA, and strong operational skills," said Mr. Pessina. "Our Board and leadership team will intensify our focus on creating value for our customers and our shareholders while we advance the search for a successor with deep healthcare experience to lead in today's dynamic environment."

    Ms. Graham said, "By capitalizing fully on the strength of WBA's strong mission, values, and brand we have an enormous opportunity to play an even more valued role in local healthcare delivery. My focus will be on our people and our operations, working together to drive shareholder value creation and ensuring a smooth transition as soon as we identify the next CEO for the future."

    For nearly three decades, Ms. Graham held leadership positions across the healthcare industry. She has served on the WBA Board of Directors since 2010, and in October 2022, was named the WBA Board Lead Independent Director. From 2003 to 2007, she was President and CEO of Amylin Pharmaceuticals, a biopharmaceutical company focused on first-in-class medicines for people with diabetes. Prior to that, she was Group Chairman, Office of the President for Guidant Corporation, a global leader in cardiology medical technology. Graham was on faculty at Harvard Business School and started her career at Eli Lilly and Company. She has served on the Boards of multiple healthcare companies and advised numerous companies and CEOs on building healthcare businesses. She is a graduate of the University of Arkansas and holds an MBA from Harvard University.

    The Company expects full-year 2023 adjusted EPS to be at or near the low end of its previously stated range. The Company will discuss 2024 guidance at its next regularly scheduled quarterly earnings call.

    About Walgreens Boots Alliance

    Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities.

    A trusted, global innovator in retail pharmacy with approximately 13,000 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. The company is reimagining local healthcare and well-being for all as part of its purpose – to create more joyful lives through better health. Through dispensing medicines, improving access to a wide range of health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare.

    WBA employs more than 325,000 people and has a presence in nine countries through its portfolio of consumer brands: Walgreens, Boots, Duane Reade, the No7 Beauty Company, Benavides in Mexico and Ahumada in Chile. Additionally, WBA has a portfolio of healthcare-focused investments located in several countries, including China and the U.S.

    The company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. WBA has been recognized for its commitment to operating sustainably: the company is an index component of the Dow Jones Sustainability Indices (DJSI) and was named to the 100 Best Corporate Citizens 2022.

    Cautionary Note Regarding Forward-Looking Statements: All statements in this release that are not historical including, without limitation, those regarding future leadership and achievement of and execution on our business and financial goals and strategy, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including those described in Item 1A (Risk Factors) of our Form 10-K for the fiscal year ended August 31, 2022 and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. These forward-looking statements speak only as of the date they are made. We do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

    WBA-GEN

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230901016638/en/

    Get the next $WBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    SEC Filings

    View All

    SEC Form 15-12G filed by Walgreens Boots Alliance Inc.

    15-12G - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

    9/8/25 1:00:15 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SCHEDULE 13G filed by Walgreens Boots Alliance Inc.

    SCHEDULE 13G - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    9/4/25 5:30:45 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form S-8 POS filed by Walgreens Boots Alliance Inc.

    S-8 POS - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

    8/28/25 3:46:00 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

    2/28/25 7:36:45 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

    Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

    2/26/24 8:28:07 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance downgraded by HSBC Securities

    HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

    2/20/24 10:23:30 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Walgreen Co. To Operate as Private Standalone Company Following Acquisition By Sycamore Partners

    Appoints Mike Motz as Chief Executive Officer Walgreen Co. ("Walgreens", or the "Company"), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company following its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in Walgreens, demonstrating their ongoing support and confidence in the Company's future. Mike Motz has been appointed as Chief Executive Officer of Walgreens effective immediately. Motz was formerly CEO of Staples US Retail, a Sycamore por

    8/28/25 8:31:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Sycamore Partners Completes Acquisition of Walgreens Boots Alliance

    Sycamore Partners ("Sycamore") announced today that it has completed its acquisition of Walgreens Boots Alliance, Inc. (the "Company" or "WBA"). Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in WBA, demonstrating their ongoing support and confidence in the Company's future. Stefan Kaluzny, Managing Director of Sycamore, said, "Walgreens Boots Alliance, Inc., its companies and its dedicated team members play an essential role in the communities they serve around the world. We look forward to partnering with the management teams at each company, including Walgreens, The Boots Group, Shields Health Solutio

    8/28/25 8:30:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Blazing Star Merger Sub, Inc. announces final results for the previously announced Tender Offer and Consent Solicitation for any and all Walgreens Boots Alliance, Inc.'s 3.600% senior notes due 2025, 2.125% senior notes due 2026, 3.450% notes due 2026, 8.125% notes due 2029, 3.200% Notes due 2030, 4.500% senior notes due 2034, 4.800% senior notes due 2044, 4.650% notes due 2046 and 4.100% Notes due 2050, and any and all of Walgreen Co.'s 4.400% notes due 2042

    NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Blazing Star Merger Sub, Inc. (the "Offeror" announced today the final results as of 5:00 p.m. (New York City time) on August 27, 2025 (the "Expiration Time"), for the previously announced cash tender offers (each, an "Offer" and, collectively, the "Tender Offer") for any and all of Walgreens Boots Alliance, Inc.'s (NASDAQ:WBA) ("WBA") outstanding (1) 3.600% senior notes due 2025 (the "2025 Notes"), (2) 2.125% senior notes due 2026 (the "2.125% 2026 Notes"), (3) 3.450% notes due 2026 (the "3.450% 2026 Notes"), (4) 8.125% notes due 2029 (the "2029 Notes"), (5) 3.200% notes due 2030 (the "2030 Notes"), (6) 4.500% senior notes due 2034 (the "2034 Notes"),

    8/27/25 7:10:00 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP Chief Corp Affairs Officer Fabbri Beth Amber L. returned 124,670 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/28/25 3:27:11 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Global CFO Mahajan Manmohan returned 414,273 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/28/25 3:26:55 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Global CLO & Corp. Sec. Minnix Lanesha returned 348,093 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/28/25 3:26:30 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/15/24 5:45:26 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/2/24 6:40:23 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    2/13/24 5:17:30 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Leadership Updates

    Live Leadership Updates

    View All

    Walgreen Co. To Operate as Private Standalone Company Following Acquisition By Sycamore Partners

    Appoints Mike Motz as Chief Executive Officer Walgreen Co. ("Walgreens", or the "Company"), America's leading independent retail pharmacy, announced today that it is now operating as a private standalone company following its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. Sycamore is acquiring the business in partnership with Stefano Pessina and his family, who have reinvested 100% of their interests in Walgreens, demonstrating their ongoing support and confidence in the Company's future. Mike Motz has been appointed as Chief Executive Officer of Walgreens effective immediately. Motz was formerly CEO of Staples US Retail, a Sycamore por

    8/28/25 8:31:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Interactive Brokers Group Set to Join S&P 500, Talen Energy to Join S&P MidCap 400 and Kinetik Holdings to Join S&P SmallCap 600

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Interactive Brokers Group Inc. (NASD: IBKR) will replace Walgreens Boots Alliance Inc. (NASD: WBA) in the S&P 500, and Talen Energy Corp. (NASD: TLN) will replace Interactive Brokers Group in the S&P MidCap 400 effective prior to the opening of trading on Thursday, August 28. Sycamore Partners is acquiring Walgreens Boots Alliance in a deal expected to be completed soon, pending final closing conditions.  Kinetik Holdings Inc. (NYSE:KNTK) will replace Pacific Premier Bancorp Inc. (NASD: PPBI) in the S&P SmallCap 600 ef

    8/25/25 5:41:00 PM ET
    $COLB
    $IBKR
    $KNTK
    Major Banks
    Finance
    Investment Bankers/Brokers/Service
    Natural Gas Distribution

    Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

    Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

    10/7/24 8:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $WBA
    Financials

    Live finance-specific insights

    View All

    Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

    Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

    7/11/25 9:59:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

    Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

    6/26/25 7:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

    Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

    4/8/25 7:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples